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Background
Idiopathic pulmonary fibrosis (IPF) is a chronic, fatal and progressive fibro-proliferative lung disease of unknown cause that leads to breathlessness and ultimately to respiratory failure and death. IPF, which is characterized by aberrant deposition of the extracellular matrix (ECM), leading to extensive lung remodeling [2] , has a median survival of 2-3 years and shows a steady incidence in older adults [1] . The disease paradigm currently centers on repetitive injury to the alveolar epithelium through the release of molecules, which results in the proliferation of resident fibroblast-to-myofibroblast differentiation, aberrantly regulated ECM deposition and, in turn, dysfunctional repair and remodeling [2] . To date, drugs targeting various molecules, such as pirfenidone and nintedanib, have been clinically used [3] , but this treatment approach has limitations. Most progressive IPF patients cannot completely recover unless they undergo lung transplantation.
Among a variety of pro-fibrotic cytokines, transforming growth factor beta 1 (TGF-β1) appears to be a key factor in the development of pulmonary fibrosis through the regulation of myofibroblast differentiation and proliferation and ECM deposition [4] . TGF-β1-mediated biological activities are regulated by intracellular signaling comprising both SMAD-dependent and SMAD-independent pathways and including mitogen-activated protein (MAP) kinase signaling. There are three major groups of MAPKs: ERK1/2, JNK/SAPK and p38 MAPK. Our previous study showed that JNK/SAPK and p38 MAPK are activated upon TGF-β1-stimulated myofibroblast differentiation [5] . In particular, p38 MAPK has been shown to ameliorate pulmonary fibrosis [6] and is thus an attractive therapeutic target in fibrosis [7] . The antifibrotic function of p38 MAPK inhibitors is believed to result from the induction of apoptosis [8] .
Eukaryotic elongation factor-2 (eEF2) kinase (eEF2K) is a member of the calmodulin kinase family of proteins and acts as a negative modulator of protein synthesis. The only known substrate of eEF2K is eEF2, which facilitates GTP-facilitated ribosomal movement from sites A to P in protein translation. Because the phosphorylation of eEF2 impairs its ribosomal binding, eEF2K inhibits eEF2 and thus slows the elongation rate. Recent studies have demonstrated that eEF2K expression and activation are increased in the pancreas and breast tumor tissues [9] . In addition, in vascular smooth muscle cells from hypertension and pulmonary hypertension (PH), activating eEF2K facilitates cell proliferation and viability [10, 11] . Both apoptosis and autophagy are processes of programmed cell death. eEF2K might modulate the expression of some apoptotic proteins, such as Bcl-XL, to inhibit the apoptotic process in cancer [12] and can regulate autophagy under environmental or metabolic stresses, including nutrient deprivation and growth factor inhibition, thereby promoting cancer cell survival [13] [14] [15] . eEF2K activity is regulated by a phosphorylation reaction that occurs downstream of various signaling pathways, such as the mTORC1, AMPK, ERK1/2 and p38 MAPK pathways [16] [17] [18] [19] .
However, the expression of eEF2K in IPF has not been reported. In this study, we demonstrate that the inactivation of eEF2K through p38 MAPK results in the dephosphorylation of eEF2 at Thr 56 and eEF2K at Ser 359, and these effects result in increased TGF-β1-induced NFL proliferation and differentiation and reduced cell apoptosis and autophagy.
Methods

Reagents and antibodies
Dulbecco's modified Eagle's medium (DMEM) was obtained from HyClone (Logan, UT, USA), and FBS was obtained from Gibco (MA, USA). Dulbecco's phosphate-buffered saline (DPBS) was purchased from Invitrogen (Waltham, MA, USA). TGF-β1 and anti-α-smooth muscle actin, anti-LC3, anti-p62 (SQSTM1), anti-eEF-2, anti-phospho-eEF-2 (Thr 56), anti-eEF2K, anti-phospho-eEF2K (Ser 359), anti-p38 MAPK, anti-phospho-p38 MAPK (Thr180/tyr182), anti-cleaved caspase-3, antiphospho-HSP 27 (Ser 82), anti-GAPDH, and anti-rabbit IgG (H+L) antibodies as well as the F(ab')2 fragment (Alexa Fluor 594 conjugate) were purchased from Cell Signaling (Danvers, MA, USA). Anti-fibronectin and anti-caspase-3 antibodies were purchased from Abcam (Cambridge, MA, USA). Anti-mouse IgG was purchased from Zhong Shan Golden Bridge Biotechnology Co., Ltd. (Beijing, Beijing, China), and goat anti-rabbit IgG was obtained from Millipore (Billerica, MA, USA). SB203580, 3-MA and rapamycin were purchased from Selleck (Shanghai, Shanghai, China), and A-484954 was acquired from SigmaAldrich (St. Louis, MO, USA).
Cell lines and culture
The human lung fibroblast cell line MRC-5 was purchased from and genetically characterized by ScienCell (Zhong Qiao Xin Zhou Biotechnology, Shanghai, China). MRC-5 cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS) at 37°C in a humidified incubator with 5% CO 2 and 95% air.
siRNA transfection
siRNA duplexes targeting eEF2K was prepared by RiboBio (Guangzhou, Guangdong, China). Non-silencing scrambled (nontargeting) siRNA was used as a control. siRNA transfection was performed according to the manufacturer's recommended protocol. Cells in the exponential phase of growth were plated in six-well plates at 1×10 5 cells per well, grown for 24 h to 30-40% confluence, transfected with siRNA for 48 h, and then identified by western blotting analysis.
Cell treatments
MRC-5 cells were transfected with siRNA-eEF2K or nontargeting siRNA for 48 h and then treated with 10 ng/ml TGF-β1 for 24 h. Additionally, MRC-5 cells were cultured in the presence of the autophagy activator rapamycin (1 mM, pre-treated for 4 h), the autophagy inhibitor 3-MA (2.5 mM, pre-treated for 4 h) or the p38 MAPK inhibitor SB203580 (8 μM, pre-treated for 2 h). Additionally, eEF2K was inhibited in the cells using the eEF2K inhibitor A-484954 (10 μM, pretreated for 2 h) for subsequent experiments.
Western blot analysis
Following the treatments, the cells were washed twice in ice-cold PBS and scraped off the tissue culture dishes. The cells were collected in microcentrifuge tubes and centrifuged at 1000×g for 5 min. The cell pellets were lysed at 4°C. Thirty micrograms of protein were resolved by 10-15% SDS-PAGE and transferred to an Immuno-Blot PVDF membrane (Millipore, Billerica, MA, USA). After blocking with 5% nonfat milk, the membrane was incubated with the appropriate antibodies. The Pierce ECL western blotting substrate kit (Pierce, Grand Island, NY, USA) was used to detect the protein signals on the immunoblots using the ECL system (Syngene, Cambridge, England, UK).
Proliferation assay
A total of 5 × 10 3 MRC-5 cells were cultured in 96-well plates with or without the indicated agents. For the assessment of cell proliferation, the cells were incubated with 20 µl of Cell Counting Kit (CCK) reagent (Beyotime Biotechnology, Shanghai, China) at 37°C for 1 h, and cell proliferation was measured based on the fluorescence at 450 nm using a 96-well plate reader (BioTek, Winooski, VT, US).
TUNEL assay
A terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay was performed as follows. A total of 1 × 10 4 cells were plated onto cover glass-bottom dishes and treated with or without the indicated agents. The cells were fixed in 4% paraformaldehyde and treated with TUNEL buffer containing fluorescein-12-dUTP for 1 h at 37°C in the dark. The slides were visualized at 200× magnification using a fluorescence microscope (Leica, Buffalo Grove, IL, USA).
Immunofluorescence
Immunofluorescence staining was performed by plating 1 × 10 4 cells onto cover glass-bottom dishes and treating the cells with or without the indicated agents. The cells on the dishes were washed three times and then fixed with 4% paraformaldehyde. The cells were then prepared and stained with rabbit polyclonal primary antibodies for LC3B (1:500) overnight at 4°C. The slides were then washed three times, incubated with FITC-conjugated anti-rabbit secondary antibody (1:40) in the dark for 1 h at 37°C, washed three times and counterstained with DAPI for 5 min at room temperature. Following staining, the slides were covered with coverslips and visualized under a fluorescence microscope (Leica, Buffalo Grove, IL, USA).
Statistical analysis
The data are shown as the means ± SEMs. Statistical evaluations were performed by one-way ANOVA followed by Bonferroni's test. Values of p < 0.05 were considered to indicate statistical significance.
Results
eEF2K inhibition aggravates the effects of TGF-β1 on fibroblast-tomyofibroblast differentiation in MRC-5 cells
eEF2K is an unusual protein kinase that regulates the elongation stage of protein synthesis by phosphorylating and inhibiting its only known substrate, eEF2. When phosphorylated on Thr 56 through its amino acid sequence, eEF2 cannot engage with ribosomes and is essentially inactive in translation [20] . eEF2K activity was inhibited in TGF-β1-treated MRC-5 cells, as demonstrated by decreased phosphorylation of eEF2 at Thr 56 (p < 0.05; Fig. 1B ) and increased cell proliferation compared with the control group (p < 0.05; Fig. 1C ). In addition, the protein expression levels of α-SMA and fibronectin were higher than those in the control group (p < 0.05; Fig. 1B ), indicating the differentiation of lung fibroblasts to myofibroblasts (p < 0.05; Fig. 1B ). We then knocked down eEF2K using siRNA-eEF2K (p < 0.05; Fig. 1A ) and found that eEF2 phosphorylation was decreased and that TGF-β1-induced fibroblast proliferation and differentiation were significantly augmented (p < 0.05; Fig. 1B, C) . A-484954 is an eEF2K inhibitor that can inhibit eEFK2 activity, resulting in the dephosphorylation of eEF2 at Thr 56 in vivo and in vitro [21] . The same results were observed in A-484954-treated cells (p < 0.05; Fig. 1D , E). Taken together, these results demonstrate that eEF2K activity is inhibited in MRC-5 cells treated with TGF-β1 and that the inhibition of eEF2K promotes fibroblast-to-myofibroblast differentiation and myofibroblast proliferation.
eEF2K inhibition induces resistance to apoptosis in MRC-5 cells treated with TGF-β1
Several studies have demonstrated that fibroblasts from fibrotic lungs are resistant to a variety of apoptotic stimuli [22, 23] . To determine the effect of eEF2K on human lung fibroblast survival, MRC-5 cells were transfected with siRNA-eEF2K for 48 h and then treated with 10 ng/ml TGF-β1 for 24 h. Apoptosis was then examined through western blot and TUNEL assays. TGF-β1 has been shown to induce lung fibroblast differentiation into myofibroblasts and inhibit cell apoptosis [24] . Our results also showed that TGF-β1 treatment significantly reduced myofibroblast apoptosis compared with the control treatment, as demonstrated by decreased cleaved caspase-3 and increased caspase-3 protein levels (p < 0.05; Fig. 2A ). The number of apoptotic cells was also reduced (p < 0.05; Fig. 2B ). The knockdown of eEF2K significantly inhibited apoptosis in MRC-5 cells treated with TGF-β1 (p < 0.05; Fig. 2A, B) . The inhibition of eEF2K by A-484954 showed a similar effect as the knockdown of eEF2K on cleaved caspase-3 and caspase-3 expression (p < 0.05; Fig. 2C ). Taken together, these results demonstrated that eEF2K inhibition induces resistance to apoptosis in MRC-5 cells treated with TGF-β1.
eEF2K inhibition suppresses autophagic activity in MRC-5 cells treated with TGF-β1
In recent years, autophagy has emerged as another mechanism of cell survival. Previous studies have shown that autophagy plays an important role in the pathogenesis of pulmonary fibrosis [25] . To determine the effect of eEF2K on human lung fibroblast autophagy, MRC-5 cells were transfected with siRNA-eEF2K and then treated with TGF-β1, and autophagy was examined through western blot and immunofluorescence staining. Our results showed that TGF-β1 treatment significantly inhibited autophagy, as evidenced by decreased LC3B, increased p62 protein levels (p < 0.05; Fig. 3A ) and diminished punctate LC3B staining (Fig. 3B ) compared with the control treatment. The inhibition of eEF2K markedly enhanced the effects on autophagy in cells treated with TGF-β1, as demonstrated by decreased LC3B, increased p62 protein levels (p < 0.05; Fig. 3A ) and lessened punctate LC3B staining (Fig. 3B) . In A-484954-treated cells, the LC3B and p62 expression levels were similar to those found with the other treatments (Fig. 3C) . It has been reported that eEF2K activity is negatively regulated by signaling through mammalian target of rapamycin complex 1 (mTORC1) [12] ; thus, we used the mTORC1 inhibitor rapamycin as an autophagic activator and 3-MA as an autophagic inhibitor to investigate whether changes in autophagic activity can alter the effect of eEF2K. Rapamycin not only up-regulated autophagic activity when eEF2K was knocked down (p < 0.05; Fig. 4A, B ) but also reduced cell proliferation (p < 0.05; Fig. 4C ) and differentiation (p < 0.05; Fig. 4A ), whereas the autophagy inhibitor 3-MA had the opposite effects of rapamycin (p < 0.05; Fig. 4A-C) . The inhibition of eEF2K with A-484954 yielded the same effects on cell autophagy, proliferation and differentiation (p < 0.05; Fig. 4D, E) . Taken together, these results demonstrate that eEF2K inhibition suppresses autophagic activity in fibroblasts treated with TGF-β1.
p38 MAPK regulates eEF2K activity in HLFs treated with TGF-β1
MAPK signaling pathways are essential to patients with IPF [26] . In our previous study, we found that the p38 MAPK signaling pathway might participate in the pathogenesis of IPF [5] . To explore the mechanism through which eEF2K inactivation enhances HLF proliferation and differentiation, we examined whether the p38 MAPK signaling pathway can regulate eEF2K in MRC-5 cells treated with TGF-β1 and [291] [292] [293] [294] [295] [296] [297] [298] found that SB203580 inhibited the TGF-β1-induced up-regulation of the phosphorylation of p38 MAPK and HSP27 (Fig. 5A) . The p38 MAPK inhibitor SB203580 prevented eEF2 dephosphorylation at Thr 56 in MRC-5 cells treated with TGF-β1 (p < 0.05; Fig. 5A ). In human epithelial KB cells, the phosphorylation of eEF2K at Ser 359 and Ser 377 increases in response to these agonists and correlates with the dephosphorylation of eEF2 [19] . In KB cells, the dephosphorylation of eEF2 at Thr 56 is resistant to SB203580 treatment [19] . In addition, SB203580 inhibits the phosphorylation of Ser 359 by TNF-α and low concentrations of anisomycin in KB cells, whereas SB203580 does not inhibit the phosphorylation of Ser 359 by high concentrations of anisomycin [19] . In our research study, we found that SB203580 treatment decreased the phosphorylation of eEF2K at Ser 359 and increased the phosphorylation of eEF2 at Thr 56 (p < 0.05; Fig. 5A ). SB203580 reversed the effects of TGF-β1 on cell differentiation and proliferation (p < 0.05; Fig. 5B , C) and activated apoptosis, as indicated by increased cleaved caspase-3 protein levels and apoptotic cell numbers and decreased caspase-3 protein levels (p < 0.05; Fig. 6 ). As shown in Fig. 7A , we found that SB203580 could activate the autophagic response, as indicated by increased LC3B expression, decreased p62 expression, and lessened punctate LC3B staining. The effects of SB203580 on autophagy were reversed by the knockdown of eEF2K (p < 0.05, Fig. 7A, B) . Furthermore, we used rapamycin and 3-MA to investigate whether the regulation of autophagy can reverse the effect of knocking down eEF2K and found that rapamycin up-regulated the autophagic activity that was inhibited by the knockdown of eEF2K (p < 0.05; Fig. 7A, B) . Rapamycin also reduced the induction of cell proliferation (p < 0.05; Fig. 7C ) and differentiation (p < 0.05; Fig. 7A ) observed in response to 
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p38 MAPK inhibition. We also repeated the experiments with A-484954 and found that siRNA-eEF2K transfection had the same effects on cell proliferation, differentiation, apoptosis and autophagy (p < 0.05; Figs. 5D-F; 6C; 7D, E). Taken together, these results demonstrated that the inhibition of eEF2K induces myofibroblast proliferation and differentiation, reduces myofibroblast apoptosis and inhibits myofibroblast autophagy through the p38 MAPK signaling pathway.
Discussion
The present study explored the role of eEF2K in the induction of fibroblast-to-myofibroblast differentiation by TGF-β1. To the best of our knowledge, this study provides the first indication that the inhibition of eEF2K induces myofibroblast proliferation and differentiation, reduces myofibroblast apoptosis and inhibits myofibroblast autophagy through the p38 MAPK signaling pathway.
IPF mainly results from alveolar epithelial injury, fibroblast-tomyofibroblast differentiation, and ECM deposition. Myofibroblasts enhance the activity of fibrogenic cytokines, particularly TGF-β1, resulting in increased ECM. Previous studies have demonstrated that TGF-β1 induces fibroblast-to-myofibroblast differentiation and excessive ECM deposition via mechanisms such as enhancing α-SMA expression, which participates in the pathogenesis of pulmonary fibrosis [27] . In this study, we found that 24-h treatment with TGF-β1 (10 ng/ml) induced fibroblast-to-myofibroblast differentiation, up-regulated α-SMA and fibronectin expression and increased lung fibroblast proliferation, which led to ECM deposition (Fig. 1). eEF2K is a unique calcium/calmodulin-dependent enzyme that regulates protein synthesis by phosphorylating its only substrate, eEF2, at Thr 56, thereby disabling the function of eEF2 in mediating ribosomal elongation during protein translation [20] . In various types of malignant carcinomas, the eEF2K/eEF2 pathway can be a key biochemical sensor linking external signals and protein synthesis, and eEF2K has been reported to be significantly up-regulated in breast and pancreatic cancer and glioma [9] . According to recent studies, eEF2K is also up-regulated in pulmonary arterial hypertension, hypertensive cardiovascular diseases and hepatitis [10, 11, 28] . In this study, we revealed that eEF2K plays a protective role in MRC-5 cells treated with TGF-β1 and leads to fibroblast-to-myofibroblast differentiation (Fig. 1) . We demonstrated that TGF-β1 treatment decreased eEF2 phosphorylation, indicating that eEF2K is inactivated in fibroblastic foci (FF) and that eEF2 is dephosphorylated and activated. The knockout of eEF2K led to decreased phosphorylation of eEF2 at Thr 56, and TGF-β1 treatment increased α-SMA and fibronectin expression and fibroblast proliferation (Fig. 1B, C) . A-484954 is an eEF2K inhibitor that can inhibit eEF2K activity and thus eEF2 phosphorylation in vivo and in vitro. We pre-treated cells with 8 μM A-484954 for 2 h before TGF-β1 treatment and found that A-484954 inhibited eEF2K activity, leading to decreased eEF2 phosphorylation and thereby the activation of eEF2, and increases in α-SMA and fibronectin expression and fibroblast proliferation were induced by TGF-β1 (Fig. 1D, E) .
Apoptosis, the best characterized programmed cell death process, 
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results in cell demise without activation of innate immune responses. The currently available evidence emphasizes the important role of apoptosis in normal lung homeostasis and in the pathogenesis of a variety of lung diseases [29] [30] [31] . Depending on the cell type, apoptosis can have helpful or harmful effects. The apoptosis of different cellular populations is involved in the pathogenesis of IPF. Myofibroblasts have been reported to acquire characteristics of apoptotic resistance [22, 23] . Our study demonstrated that the apoptosis of HLFs decreased after treatment with TGF-β1 (Fig. 2) . In tumor cells, the inactivation of eEF2K might promote apoptosis under various stress conditions. An interesting and important finding of our study is that eEF2K inactivation might inhibit myofibroblast apoptosis (Fig. 2) . We found that the knockout of eEF2K in MRC-5 cells treated with TGF-β1 decreased the number of apoptotic cells and the expression of cleaved caspase-3 protein and increased caspase-3 expression. A-484954 treatment also decreased the expression of cleaved caspase-3 and increased caspase-3 expression. These findings reveal that eEF2K inactivation can inhibit myofibroblast apoptosis. Studies have shown that autophagy is inhibited in human IPF, and insufficient autophagy in lung fibroblasts leads to myofibroblast differentiation and increased ECM production, both of which are critical steps in the fibrogenic process [25] . Our findings provide evidence indicating that TGF-β1 treatment leads to the inhibition of autophagy in HLFs (Fig. 3) . A connection between eEF2K and autophagy has been reported in different cell lines. However, the role of eEF2K in autophagy is controversial. In glioma and breast cancer cells, the blockage of eEF2K might disrupt the onset of autophagy, thereby limiting autophagic survival [13, 32] . However, in colon cancer cells, the silencing of eEF2K induces autophagy and promotes cell survival [17] . Another study showed that eEF2K protects colon carcinoma and lung carcinoma cells against nutrient starvation by inhibiting protein synthesis rather than by activating autophagy [33] . Our study found that eEF2K inhibition exacerbated the inhibition of myofibroblast autophagy (Fig. 3) . We provide evidence showing decreased LC3B levels and punctate LC3B staining and increased p62 protein levels. We found that the activation of autophagy with rapamycin can reverse the effect of the knockdown of eEF2K in fibroblasts treated with TGF-β1, including decreased α-SMA and fibronectin expression, and the inhibition of autophagy with 3-MA can aggravate the effect of the knockdown of eEF2K in HLFs (Fig. 4) . The use of A-484954 as an eEF2K inhibitor also led to the inhibition of myofibroblast autophagy. These findings reveal that the inactivation of eEF2K might aggravate the inhibition of autophagy in fibroblast-to-myofibroblast differentiation.
MAPKs are involved in crucial signaling pathways involved in cell proliferation, differentiation and death in response to various signals produced by growth factors, hormones and cytokines. There are three major groups of MAPKs: ERK1/2, JNK/SAPK and p38 MAPK. Our previous study showed that JNK/SAPK and p38 MAPK are activated upon TGF-β1-stimulated myofibroblast differentiation [5] . It has been reported that in human KB cells, SB203580 prevents the dephosphorylation of eEF2 [19] . As demonstrated in HLFs pre-treated with the p38 MAPK inhibitor SB203580, SB203580 induced eEF2 phosphorylation at Thr 56 and inhibited eEF2K phosphorylation at Ser 359, which led to the activation of eEF2K (Fig. 5A) . Furthermore, our findings showed that the inhibition of eEF2K promotes cell differentiation and proliferation and that these effects were weakened by the inhibition of p38 MAPK (Fig. 5B, C) . Additionally, SB203580 can promote TGF-β1-inhibited apoptosis, and the inhibition of eEF2K blocked the effect of SB203580 on apoptosis (Fig. 6 ). The inhibition of p38 MAPK by SB203580 induced TGF-β1-inhibited autophagy, but the inhibition of eEF2K reversed the effect of SB203580. In addition, rapamycin can reverse the effect of eEF2K inhibition, and 3-MA can promote the effect of eEF2K inhibition (Fig. 7) . These results reveal a signaling pathway consisting of p38 MAPK eEF2K/eEF2 that participates in lung fibroblast proliferation, differentiation, apoptosis and autophagy.
Conclusions
In summary, the present study provides the first demonstration that the inactivation of eEF2K leads to the dephosphorylation of eEF2 via the p38 MAPK signaling pathway and contributes to lung fibroblast proliferation and differentiation and reduced lung fibroblast apoptosis and autophagy, all of which might contribute to fibroblast-to-myofibroblast differentiation. Further studies are needed to elucidate the mechanism through which eEF2K mediates phenotypic changes in human fibroblasts and regulates other signaling pathways, such as AMPK/mTOR signaling.
